Vertex Pharmaceuticals’ $4.9 billion plunge into kidney disease is looking a lot less like a gamble and a lot more like a carefully calculated win, after the Boston company rolled out impressive interim data from its pivotal Phase 3 program this week. The strong showing puts Vertex on an accelerated track with regulators as it races to wrap up a U.S. filing in the coming weeks.
Trial data shows deep drops in proteinuria
In a pre-specified Week 36 look at the global Phase 3 RAINIER study, patients on povetacicept logged a 52.0% reduction from baseline in 24-hour urine protein to creatinine ratio (UPCR). On a placebo-adjusted basis, that translated to a 49.8% reduction (P<0.0001). The trial also cleared two alpha-controlled secondary endpoints: roughly a 77% drop in serum galactose-deficient IgA1 and hematuria resolution in 85.1% of povetacicept-treated patients compared with 23.4% on placebo. Vertex said the drug was generally safe and well tolerated, according to a company press release on Business Wire.
Regulatory sprint: BLA due by month end
Vertex has told investors it plans to finish a Biologics License Application for povetacicept by the end of March and is aiming for accelerated approval in the U.S. The company’s filing schedule and next regulatory moves were outlined by the Boston Business Journal.
How Vertex landed the program
To get its hands on povetacicept, Vertex shelled out about $4.9 billion in April 2024 to acquire Alpine Immune Sciences, the largest deal in the company’s history and the foundation of its push into kidney medicine. The acquisition has been cast as the launchpad for Vertex’s broader renal franchise and was widely covered at the time by outlets including CNBC.
What this means for patients and the pipeline
If regulators sign off, Vertex said it plans to offer povetacicept as a low-volume subcutaneous auto-injector given once every four weeks for at-home use. The company also flagged its intent to move the medicine into additional kidney indications and confirmed that the RAINIER trial will stay blinded through a full two-year analysis, per the company release on Business Wire.
Boston angle and market reaction
Headquartered in Boston’s Seaport District, Vertex is using povetacicept’s success to anchor a fourth major franchise beyond cystic fibrosis, hematology and acute pain, according to the company careers page. Wall Street liked what it saw: Vertex shares edged higher after the data hit, as reported by The Boston Globe.
